Amanda Leverett Davis was diagnosed with an aggressive bone cancer called chondroblastic osteosarcoma in March of 2017. By the time her doctors discovered it, the disease had metastasized and advanced to stage 3. Amanda was told it was non-curative. But nearly two years after her initial diagnosis, Amanda is still alive to share her story, and […]
Continue reading
The KEYNOTE-054 Phase 3 clinical trial (NCT02362594) showed that the immune checkpoint inhibitor drug Keytruda decreased the risk of melanoma recurrence or death by 43% in comparison to a placebo drug. The drug has thus been approved by the U.S. Food and Drug Administration (FDA) to treat patients with stage-3 melanoma (cancer has spread to […]
Continue reading
Amanda D. came to CHIPSA Hospital last October looking for ways to improve her quality of life after surgery, radiation, and chemotherapy failed to treat her late-stage cancer. But she believes CHIPSA did more than that. According to her, not only did they improve her quality of life, they also extended it. Amanda […]
Continue reading
A recent report in the journal Cell showed that a team led by Vanderbilt researchers has found a new “checkpoint” protein on immune system cells in active, malignant tumors. In mouse models, blocking this protein, along with using other treatments, has been an effective approach to treating cancerous cells. Checkpoint proteins are an important component of […]
Continue reading
How Charlotte T. Beat Stage 4 Cancer at CHIPSA Hospital Charlotte T. thought she was out of options when she was diagnosed with Stage-4 inoperable Endometrial cancer in November of 2017. After having a full hysterectomy and 25 rounds of radiation, her doctors told her that the cancer had metastasized to her lungs. There was […]
Continue reading
A recent study published in Nature Genetics called “Tumor mutational load predicts survival after immunotherapy across multiple cancer types” revealed that tumors with more mutations had better results with immunotherapy treatment. The study looked at data from 1,662 metastatic cancer patients who received checkpoint inhibitor therapy, and data from over 5,000 patients who were not treated […]
Continue reading
People from all around the world are reading about Chipsa and then heading to CHIPSA Hospital in Mexico to treat their cancer. Our full-service community hospital overlooking the Pacific Ocean in Playas de Tijuana offers several integrative treatments and immunological therapies. We treat patients at all stages, including those with advanced, late-stage disease. It […]
Continue reading
A research team from the University of Maryland is utilizing artificial intelligence (AI) to determine the most effective ways to treat cancer patients with immunotherapy. Immunotherapy takes advantage of the body’s own immune system to fight off cancer, and in the past decade, it has been very successful in treating patients with localized and advanced […]
Continue reading
The ORIENT-15 Phase 3 clinical trial evaluating Tyvyt (sintilimab injection) combined with chemotherapies Taxol (paclitaxel) and Platinol (cisplatin) as treatment for esophageal squamous cell carcinoma is now underway. Tyvyt was developed by Innovent Biologics and Eli Lilly and Company in China as an immune checkpoint inhibitor that will work against PD-1, a protein found on […]
Continue reading
Genetech has announced that the U.S. Food and Drug Administration (FDA) will be reviewing its Tecentriq (atezolizumab) combined with chemotherapy drugs Abraxane (nab-paclitaxel) and carboplatin for treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The drug will be for patients without any mutations in the EGFR and ALK genes. Tecentriq is a checkpoint inhibitor drug that targets […]
Continue reading